Group 1: Company Performance - In the first half of 2025, the company achieved a revenue of 5.34 billion yuan, representing a year-on-year growth of 14.75% [3] - The net profit attributable to shareholders reached 25.38 million yuan, with a significant year-on-year increase of 140.35% [3] - The company's gross margin has improved significantly, indicating a fundamental enhancement in its financial health [3] Group 2: Strategic Planning - The company is focusing on a "one-stop service platform" for drug development, promoting a full-package service model to reduce communication costs and enhance efficiency [3] - The integration of AI technology into drug research and development is a key strategy, with successful applications in multiple core business areas [3] - The company aims to leverage its technological service capabilities to fill critical gaps in the industry chain and foster collaborative ecosystems [3] Group 3: Market Expansion - Over 80% of the company's revenue comes from overseas clients, with approximately 20% from the Asia-Pacific region [4] - The company is actively expanding its presence in the Asia-Pacific market and enhancing its service capabilities in Europe and the US [4] - New modality drug business has seen a significant increase, with orders from XDC and peptides rising from 8% to 17% year-on-year [5] Group 4: Customer Strategy - The company aims to secure long-term contracts with multinational corporations (MNCs) while also empowering more biotech firms as long-tail customers [5] - The customer structure is primarily composed of small to medium biotech firms, with a trend of MNC clients returning [5] - The company is focusing on enhancing collaboration with MNCs to stabilize its customer base and performance [5] Group 5: Financial Goals and Milestones - The long-term strategic goal is to capture 1% of the global CXO market, which is valued at 1 trillion USD [7] - The company targets a revenue increase to 2.5 billion yuan and a net profit of no less than 200 million yuan by 2027 [7] - Key milestones for the upcoming year include enhancing full-package services, establishing laboratories in Boston and the UK, and improving overall service capabilities [8]

Group 1: Company Management and Strategy - The company has optimized its management system by scientifically configuring the management team and clarifying responsibilities, resulting in a stable and efficient organizational structure [2][3] - The marketing and client expansion system has been strengthened, with the business development (BD) team expanding from over 10 to nearly 30 members, including the establishment of dedicated teams for the US and Europe [2][3] - The company has established a clear development strategy focused on "full-package services," enhancing its one-stop service capability from target discovery to IND application [3] Group 2: Service Model and Market Focus - The company promotes a full-package service model in the domestic market, which effectively reduces communication costs and ensures efficient process integration, crucial for high-investment, long-cycle biopharmaceutical R&D [4] - The primary target clients for the full-package services include domestic innovative biotech companies, traditional pharmaceutical companies transitioning to innovative drugs, and research projects from academic institutions [4] Group 3: Technological Advancements - The company has completed the localization of the DeepSeek platform, which is now applied in experimental data analysis, research report generation, and knowledge graph construction, significantly improving R&D efficiency [5] - The company is collaborating with external R&D teams to explore AI-enabled CRO services to further enhance innovative drug development efficiency [5] Group 4: Core Competitiveness - The company boasts 23 years of professional service experience, a wealth of target research data, and a comprehensive R&D platform, continuously advancing in new modality drug platform construction [6] - As one of the few CROs in China with full-process service capability from target to IND, the company offers a unique competitive advantage by providing comprehensive solutions from target identification to commercial production [6] Group 5: Business Performance and Projections - The pharmacology and pharmacokinetics business has surpassed 50% of the company's core business segments as of 2024, with a balanced growth trend between large and small molecule businesses, where large molecule orders slightly exceed small molecule orders [8]